Cantor Fitzgerald Forecasts Strong Price Appreciation for Progyny (NASDAQ:PGNY) Stock

Progyny (NASDAQ:PGNY) had its target price upped by investment analysts at Cantor Fitzgerald from $31.00 to $35.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald‘s price target would indicate a potential upside of 16.28% from the stock’s previous close.

Several other equities research analysts have also recently weighed in on PGNY. KeyCorp upped their target price on Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Truist Financial lifted their price target on Progyny from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Citigroup restated a “market outperform” rating on shares of Progyny in a research report on Thursday. Wall Street Zen lowered Progyny from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 31st. Finally, Citizens Jmp lifted their target price on Progyny from $31.00 to $33.00 and gave the company a “market outperform” rating in a research report on Tuesday, September 8th. Ten research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Progyny Stock Up 3.6%

PGNY opened at $30.10 on Thursday. The stock has a market capitalization of $2.31 billion, a price-to-earnings ratio of 32.72, a P/E/G ratio of 2.01 and a beta of 0.97. Progyny has a twelve month low of $16.10 and a twelve month high of $33.06. The company has a 50-day simple moving average of $27.11 and a 200 day simple moving average of $24.49.

Progyny (NASDAQ:PGNY) last issued its earnings results on Wednesday, November 4th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.31 by $0.21. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The company had revenue of $341.25 million during the quarter, compared to analysts’ expectations of $340.76 million. During the same period in the previous year, the company earned $0.15 EPS. The business’s revenue for the quarter was up 8.9% compared to the same quarter last year. Sell-side analysts anticipate that Progyny will post 1.25 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, COO Melissa B. Cummings sold 1,879 shares of the stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $28.00, for a total value of $52,612.00. Following the completion of the transaction, the chief operating officer directly owned 66,496 shares in the company, valued at approximately $1,861,888. This represents a 2.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin K. Gordon sold 11,500 shares of the firm’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $27.94, for a total value of $321,310.00. Following the sale, the director directly owned 6,792 shares in the company, valued at approximately $189,768.48. This trade represents a 62.87% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 17,282 shares of company stock valued at $475,790. 9.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Progyny

A number of institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of Progyny during the second quarter valued at about $334,426,000. Bank of America Corp DE acquired a new position in shares of Progyny in the second quarter valued at approximately $17,264,000. William Blair Investment Management LLC acquired a new position in shares of Progyny in the second quarter valued at approximately $16,807,000. Danske Bank A S acquired a new position in shares of Progyny in the second quarter valued at approximately $15,243,000. Finally, Jupiter Topco LLC bought a new position in Progyny in the 2nd quarter valued at approximately $12,986,000. Institutional investors and hedge funds own 94.93% of the company’s stock.

Trending Headlines about Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported third-quarter EPS of $0.52, up from $0.15 a year earlier, and revenue of $341.25 million, an 8.9% year-over-year increase. Revenue narrowly topped one estimate of $340.76 million; the company characterized the quarter as a record. Progyny Announces Third Quarter 2026 Results
• Neutral Sentiment: Analyst benchmarks differed: one source cited a $0.31 EPS consensus, while Zacks cited $0.51. Thus, the earnings beat appears substantial against the lower estimate but modest against the higher one, while revenue was close to expectations. Progyny Tops Q3 Earnings and Revenue Estimates

About Progyny

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.